Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Study Links Smoking in College to Other Risky Student Behaviors

March 1, 1998
Publication
Article
OncologyONCOLOGY Vol 12 No 3
Volume 12
Issue 3

College students who smoke not only are endangering their health but also are likely to have adopted other risky behaviors. A new study by researchers at Dana-Farber Cancer Institute and the Harvard School of Public Health has found that college students who smoke are more likely to use marijuana and other illegal drugs, to be sexually promiscuous, and to be uninvolved in sports and athletic activities.

College students who smoke not only are endangering their health but also are likely to have adopted other risky behaviors. A new study by researchers at Dana-Farber Cancer Institute and the Harvard School of Public Health has found that college students who smoke are more likely to use marijuana and other illegal drugs, to be sexually promiscuous, and to be uninvolved in sports and athletic activities.

The study, published in the January issue of the American Journal of Public Health, suggests that encouraging students to participate in more productive aspects of campus life might have the additional benefit of deterring them from smoking.

“College presents an opportunity to reach smokers while society still has ‘institutional’ access to them,” says study coauthor Karen Emmons, PhD, of Dana-Farber and the Harvard School of Public Health. “Smoking should serve as a warning sign to resident assistants and other college counselors that these students need to be drawn more fully into college life.”

Large Number of Students Surveyed
The study is based on a survey of more than 17,000 students at 140 four-year colleges across the country. Students were asked to complete a questionnaire about their use of alcohol, cigarettes, and illicit drugs and to provide information on their living arrangements, lifestyle, and academic performance.

Analysis of the survey showed that 22% of the students had smoked within the previous 30 days and 25% were former smokers—meaning that almost half of all students surveyed had smoked at some point in their lifetime. Among the current smokers, 34% smoked at least half a pack a day and 14% smoked a pack or more a day. College smoking was found to be linked with a variety of behaviors that are either physically or psychologically unhealthy. Students who engaged in binge-drinking prior to college, for example, were almost twice as likely to smoke in college than students who did not binge-drink. Students who smoked were also more likely to use marijuana and to have had multiple sex partners during the previous month.

Lifestyle Choices Influence Smoking
Lifestyle choices were shown to exert a powerful influence on student smoking. Researchers found that smokers were less likely to participate in intercollegiate athletics (a trend that held for male students only) and tended to be less involved in community service, religion, arts, and productive activities and to be more involved in leisure activities. Membership in a fraternity or sorority also increased the likelihood of being a smoker, as did frequent attendance at parties.

One intriguing finding of the study was that risk-taking behavior was an even more powerful predictor of smoking in female students than in their male counterparts.

“Clearly, there is a strong association between students’ lifestyle and the decision of whether or not to smoke,” Emmons says. “The link between high school binge drinking and college smoking may indicate that smoking among college students is part of a risk-taking lifestyle initiated well before college.”

Encouraging Healthy Lifestyles
Fortunately, colleges and universities have at their disposal a variety of options for encouraging healthy lifestyles among students, Emmons notes, from policies banning smoking in university buildings to programs encouraging involvement in the arts, sports, and community service. “By instituting strong policies regarding smoking, universities can establish norms about what values and activities they consider acceptable and what they don’t,” she says.

Part of the challenge facing universities in formulating such policies is that student behavior so often seems contradictory. Participation in intercollegiate sports, for instance, seems to discourage smoking but has been associated with binge-drinking. “It’s important for colleges to take a multifaceted approach to these problems,” Emmons says. “They need to give students the confidence that if they can change one risk behavior, they can change another.”

The difficulty of making and enforcing such policies should not deter colleges from the effort, she remarks. “College is a transitional time in young people’s lives. It’s a time to try and figure out what your lifestyle is going to be like in the future. Colleges and universities have a responsibility to help shape those decisions in healthy directions.”

Emmons’ coauthors on the study were Henry Wechsler, PhD, and Melissa Abraham of the Harvard School of Public Health, and George Dowdall, PhD, of St. Joseph’s University in Philadelphia.

Articles in this issue

Preclinical Studies Using the Intratumoral Aromatase Model for Postmenopausal Breast Cancer
Phase II and III Clinical Trials of Toremifene for Metastatic Breast Cancer
Status of Antiestrogen Breast Cancer Prevention Trials
Antiestrogen Therapy: Uncertainties and Risk Assessment
Adjuvant Trials of Toremifene vs Tamoxifen: The European Experience
Pivotal Trials of Letrozole: A New Aromatase Inhibitor
Emerging Role of Aromatase Inhibitors in the Treatment of Breast Cancer
SGO Clinical Practice Guidelines: Introductory Remarks
Scientists Define New Role for Cell Signaling Pathway
Coalition Formed to Further Clinical Cancer Research
New Genetic Defect Signals Need for Aggressive Leukemia Treatment
Investigators Involved in Toremifene Studies Call It a Potentially Safer Antiestrogen
New Kind of Vaccine Aimed at Disseminated Melanoma
Steroid Improves Cancer-Fighting Ability of Vitamin D Analog
Study Links Smoking in College to Other Risky Student Behaviors
Recent Videos
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
2 experts are featured in this series.
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
2 experts are featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Related Content
Advertisement

Adverse reactions in the phase 3 ENVISION trial were largely mild to moderate in severity, and serious reactions occurred in 12% of those with NMIBC.

Mitomycin Exhibits Durable Responses in Recurrent, Low-Grade NMIBC

Roman Fabbricatore
August 7th 2025
Article

Adverse reactions in the phase 3 ENVISION trial were largely mild to moderate in severity, and serious reactions occurred in 12% of those with NMIBC.


Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Jacob Sands, MD
August 4th 2025
Podcast

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.


The FDA has accepted a new drug application for the prostate-specific membrane antigen PET imaging agent.

FDA Accepts NDA for New Formulation of PSMA PET Injection in Prostate Cancer

Tim Cortese
August 7th 2025
Article

The new formulation should increase the batch size by approximately 50% and will offer the potential to expand access to patients in new geographic locations.


Navigating Second-Line Treatment Options in Urothelial Carcinoma

Navigating Second-Line Treatment Options in Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
July 31st 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.


The CAR-T yielded a manageable safety profile in patients with mantle cell lymphoma.

Novel Treatment Receives FDA RMAT Designation in R/R Mantle Cell Lymphoma

Tim Cortese
August 7th 2025
Article

The anti-CD19/4-1BB CAR T-cell therapy candidate elicited an ORR and CR rate of 100% each in patients with relapsed/refractory MCL.


Patients reclassified to high-risk clinicopathology with DCISionRT saw an absolute reduction in IBR rates of 11.6%; from 17.7% to 6.1%.

DCISionRT Shows Superiority vs Clinicopathology in Predicting DCIS Risk

Roman Fabbricatore
August 6th 2025
Article

Patients reclassified to high-risk clinicopathology with DCISionRT saw an absolute reduction in IBR rates of 11.6%; from 17.7% to 6.1%.

Related Content
Advertisement

Adverse reactions in the phase 3 ENVISION trial were largely mild to moderate in severity, and serious reactions occurred in 12% of those with NMIBC.

Mitomycin Exhibits Durable Responses in Recurrent, Low-Grade NMIBC

Roman Fabbricatore
August 7th 2025
Article

Adverse reactions in the phase 3 ENVISION trial were largely mild to moderate in severity, and serious reactions occurred in 12% of those with NMIBC.


Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Jacob Sands, MD
August 4th 2025
Podcast

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.


The FDA has accepted a new drug application for the prostate-specific membrane antigen PET imaging agent.

FDA Accepts NDA for New Formulation of PSMA PET Injection in Prostate Cancer

Tim Cortese
August 7th 2025
Article

The new formulation should increase the batch size by approximately 50% and will offer the potential to expand access to patients in new geographic locations.


Navigating Second-Line Treatment Options in Urothelial Carcinoma

Navigating Second-Line Treatment Options in Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
July 31st 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.


The CAR-T yielded a manageable safety profile in patients with mantle cell lymphoma.

Novel Treatment Receives FDA RMAT Designation in R/R Mantle Cell Lymphoma

Tim Cortese
August 7th 2025
Article

The anti-CD19/4-1BB CAR T-cell therapy candidate elicited an ORR and CR rate of 100% each in patients with relapsed/refractory MCL.


Patients reclassified to high-risk clinicopathology with DCISionRT saw an absolute reduction in IBR rates of 11.6%; from 17.7% to 6.1%.

DCISionRT Shows Superiority vs Clinicopathology in Predicting DCIS Risk

Roman Fabbricatore
August 6th 2025
Article

Patients reclassified to high-risk clinicopathology with DCISionRT saw an absolute reduction in IBR rates of 11.6%; from 17.7% to 6.1%.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.